en · de · es · pt
semax-notes.peptides7501.com › Wiki › Background And Development History — Practical Notes

Background And Development History — Practical Notes

By Editorial Desk · published 2025-09-08 · last reviewed 2025-09-22 · Wiki

This is a working overview of ACTH analog, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-09-22 and is reviewed periodically as new material appears.

Background and Development History

The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.

Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.

Semax Peptide Structure and Origin

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.

Semax at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideAnalogue of the ACTH(4-10) fragment
Amino acid sequenceMet-Glu-His-Phe-Pro-Gly-ProSingle-letter form MEHFPGP
Molecular formulaC37H51N9O10SFree peptide, nominal mass near 814 Da
First registration1994, RussiaNasal formulation for neurological indications
Typical purity grade95% or higher by HPLCResearch material; higher grades used as reference standards

Background and Development

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Related pages on this site

Semax Peptide Background and Identity

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.

Semax Background and Chemistry

Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.

The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.

Notes from published material

== History == The first modern report of sickle cell disease may have been in 1846, where the autopsy of an executed runaway slave was discussed; the key finding was the absence of the spleen. Reportedly, African slaves in the United States exhibited resistance to malaria, but were prone to leg ulcers. The abnormal characteristics of the red blood cells, which later lent their name to the condition, were first described by Ernest E. Irons (1877–1959), intern to Chicago cardiologist and professor of medicine James B. Herrick (1861–1954), in 1910. Irons saw "peculiar elongated and sickle-shaped" cells in the blood of a man named Walter Clement Noel, a 20-year-old first-year dental student from Grenada. Noel had been admitted to the Chicago Presbyterian Hospital in December 1904 with anaemia. Noel was readmitted several times over the next three years for "muscular rheumatism" and "bilious attacks" but completed his studies and returned to the capital of Grenada (St. George's) to practice dentistry. He died of pneumonia in 1916 and is buried in the Catholic cemetery at Sauteurs in the north of Grenada. Shortly after the report by Herrick, another case appeared in the Virginia Medical Semi-Monthly with the same title, "Peculiar Elongated and Sickle-Shaped Red Blood Corpuscles in a Case of Severe Anemia." This article is based on a patient admitted to the University of Virginia Hospital on 15 November 1910. In the later description by Verne Mason in 1922, the name "sickle cell anemia" is first used.

Murphy (1949), professor of anthropology at Columbia University Arthur Melvin Okun (1949), chairman of the Council of Economic Advisers, proposed Okun's law William Rubin (1949), curator at the Museum of Modern Art James P. Shenton (1949), historian, professor of Columbia University, mentor of Bancroft Prize winners John D. Rosenberg (1950), scholar of Victorian literature, professor at Columbia University Burton Watson (1950), scholar and translator of Chinese and Japanese literature George Keller (1951), professor of higher education studies at the University of Pennsylvania Joseph Rothschild (1951), professor of Central European and Eastern European history at Columbia University Immanuel Wallerstein (1951), sociologist who defined world-systems theory A. James Gregor (1952), professor of political science at the University of California, Berkeley George Kateb (1952), professor of political science at Princeton University Elliott Mendelson (1952), logician; professor of mathematics at Queens College, City University of New York Andrew P.

In the life sciences, a contract research organization or clinical research organization (CRO) is a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. A CRO may provide such services as biopharmaceutical development, biological assay development, commercialization, clinical development, clinical trials management, pharmacovigilance, outcomes research, and real world evidence. CROs are designed to reduce costs for companies developing new medicines and drugs in niche markets. They aim to simplify entry into drug markets, and simplify development, as the need for large pharmaceutical companies to do everything ‘in house’ is now redundant. CROs also support foundations, research institutions, and universities, in addition to governmental organizations (such as the NIH, EMA, etc.). Many CROs specifically provide clinical-study and clinical-trial support for drugs and/or medical devices. However, the sponsor of the trial retains responsibility for the quality of the CRO's work. CROs range from large, international full-service organizations to small, niche specialty groups. CROs that specialize in clinical-trials services can offer their clients the expertise of moving a new drug or device from its conception to FDA/EMA marketing approval, without the drug sponsor having to maintain a staff for these services. Organizations who have had success in working with a particular CRO in a particular context (e.g.

has stated that these are the only actions known at present which could explain or at least contribute to the antidepressant effects of trimipramine. That said, blockade of the 5-HT2A, 5-HT2C, and α2-adrenergic receptors, as with mirtazapine, has also been implicated in antidepressant effects. In any case, there is also clinical and animal evidence that trimipramine does not inhibit the reuptake of monoamines. Unlike other TCAs, it does not downregulate β3-adrenergic receptors, which is likely the reason that it does not cause orthostatic hypotension. It can be safely combined with MAOIs apparently without risk of serotonin syndrome or hypertensive crisis. Indeed, in rabbits, whereas hyperpyrexia (a symptom of serotonin syndrome) occurs with imipramine and an MAOI and to a lesser extent with amitriptyline and an MAOI, it does not occur at all with trimipramine and an MAOI, likely due to trimipramine's lack of serotonin reuptake inhibition.

== Chemistry == Levodopa is an amino acid and a substituted phenethylamine and catecholamine. Analogues and prodrugs of levodopa include melevodopa, etilevodopa, foslevodopa, and XP-21279. Some of these, like melevodopa and foslevodopa, are approved for the treatment of Parkinson's disease similarly to levodopa. Other analogues include methyldopa, an antihypertensive agent, and droxidopa (L-DOPS), a norepinephrine precursor and prodrug. 6-Hydroxydopa, a prodrug of 6-hydroxydopamine (6-OHDA), is a potent dopaminergic neurotoxin used in scientific research.

Sources: en.wikipedia.org

Further detail

=== Light limitation === Brine pockets can form deep within sea ice where there is very low irradiance. Since snow and ice block and reflect incoming light, with deeper brine pockets experience more light limitation than shallower brine pockets. When salts in seawater become rejected during the ice formation, these salts can precipitate and accumulate within the ice, influencing the ability of light to pass through the ice. Given that more salts will precipitate with colder temperatures as brine becomes more concentrated, colder temperatures can result in a greater change to the optics of the ice as more salts accumulate. Lower light levels in brine pockets can impact the survivability of photosynthetic organisms such as cyanobacteria and diatoms. These organisms have developed adaptations so that they can survive in this extremely light-limited environment.

=== Supercritical water hydrolysis === Supercritical hydrolysis is a method of converting all biomass polysaccharides as well the associated lignin into low molecular compounds by contacting with water alone under supercritical conditions. The supercritical water, acts as a solvent, a supplier of bond-breaking thermal energy, a heat transfer agent and as a source of hydrogen atoms. All polysaccharides are converted into simple sugars in near-quantitative yield in a second or less. The aliphatic inter-ring linkages of lignin are also readily cleaved into free radicals that are stabilized by hydrogen originating from the water. The aromatic rings of the lignin are unaffected under short reaction times so that the lignin-derived products are low molecular weight mixed phenols. To take advantage of the very short reaction times needed for cleavage a continuous reaction system must be devised. The amount of water heated to a supercritical state is thereby minimized.

Arsène Charles Ernest Wenger (born 22 October 1949) is a French former football manager and player who has been serving as FIFA's Chief of Global Football Development since 2019. Nicknamed Le Professeur, he is widely regarded as one of the most influential football managers of his generation. Wenger was the manager of Arsenal from 1996 to 2018, becoming the longest-serving and most successful manager in the club's history and the longest-serving manager in the history of the Premier League. Born in Strasbourg and raised in Duttlenheim, Wenger was introduced to football by his father, the manager of the local village team. After a modest playing career as a midfielder, with appearances for clubs including FC Mulhouse and RC Strasbourg, he obtained a manager's diploma in 1981. Wenger began his managerial career at Nancy in 1984 before joining Monaco in 1987. At Monaco, he won the French league title and the Coupe de France in 1991. In 1995, Wenger moved to Japan to manage Nagoya Grampus Eight, where he won both the Emperor's Cup and the Japanese Super Cup. In 1996, Wenger was appointed manager of Arsenal. Initially greeted with scepticism by the English media, he went on to transform the club and English football through innovations in nutrition, training methods, and global scouting. He became the first foreign manager to win a Premier League and FA Cup double in 1998, repeated the feat in 2002, and led Arsenal to an unbeaten league title in 2004. His team later set an English record of 49 consecutive league matches unbeaten.

== External links == Media related to Yugoslavia national association football team at Wikimedia Commons RSSSF – Yugoslavia men's national football team international matches 1920–1992 (in English) RSSSF – Yugoslavia men's national football team international matches + Serbia and Montenegro and Serbia (in English) Yugoslavia national football team web page (in Serbian)

Sources: en.wikipedia.org

Supporting material

During the first phase, from 1804 to 1806, it was a conservative reaction to new abuses by the Janissaries and Dahis, after they killed Hadji Mustafa Pasha (vizier of the Sanjak of Smederevo). He had created a militia of Serbs fighting the Janissaries that were expelled from Belgrade and had found refuge with Osman Pazvantoğlu, governor of the Sanjak of Vidin (in present-day Bulgaria), who pursued his own policy and sought independence, which brought him into conflict with the Serbs and later with the Sublime Porte. The Janissaries managed to return to Belgrade and realized the Slaughter of the Knezes. Thus, the Serbs appealed to Sultan Selim III for assistance against the Dahis, who had since rejected the authority of the Porte. Also, Karađorđe negotiated with the Austrian captain Sajtinski. At this meeting, he expressed the wish of the Serbian people that the Austrian Empire receive them as a kingdom under its protection like in the past, as occupation of 1788–1791 was still a fresh memory. However, the Austrian authorities, due to difficulties with Napoleon and because they wanted to maintain their neutrality in order to be correct with the Porte, could not accept his offers. So, the Serbs were forced to ask for the protection of the Russians, and therefore, on 3 May 1804, the Serb leaders sent a letter to the Russian envoy in Constantinople, in which they spoke of the problems and wishes of the Serbian people, but they also stressed that they would continue to be loyal to the Sultan.

However, as the atrial baroreceptors increase their rate of firing and as they stretch due to the increased blood pressure, the cardiac center responds by increasing sympathetic stimulation and inhibiting parasympathetic stimulation to increase heart rate. The opposite is also true. Chemoreceptors present in the carotid body or adjacent to the aorta in an aortic body respond to the blood's oxygen, carbon dioxide levels. Low oxygen or high carbon dioxide will stimulate firing of the receptors. Exercise and fitness levels, age, body temperature, basal metabolic rate, and even a person's emotional state can all affect the heart rate. High levels of the hormones epinephrine, norepinephrine, and thyroid hormones can increase the heart rate. The levels of electrolytes including calcium, potassium, and sodium can also influence the speed and regularity of the heart rate; low blood oxygen, low blood pressure and dehydration may increase it.

NH3 + 5-glutamyl-D-glutamyl-peptide The 3 substrates of this enzyme are L-glutamine, D-glutamine, and D-glutamyl-peptide, whereas its two products are NH3 and 5-glutamyl-D-glutamyl-peptide. This enzyme belongs to the family of transferases, specifically the aminoacyltransferases. The systematic name of this enzyme class is glutamine:D-glutamyl-peptide 5-glutamyltransferase. Other names in common use include D-glutamyl transpeptidase, and D-gamma-glutamyl transpeptidase. This enzyme participates in d-glutamine and d-glutamate metabolism.

Sources: en.wikipedia.org

Frequently asked questions

In which form is semax typically supplied?

Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.

Does semax occur naturally?

No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.

Why is it grouped with nootropics?

The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.

What is Semax chemically?

It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.

Network